Fundraising Fox
/Companies
Sign in

Tiltbio

Helsinki, FI · Founded 2013 · 27 employees on LinkedIn · 3 known investors

Find your way into Tiltbio

Sign up to see every warm intro you have to Tiltbio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Tiltbio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

TILT Biotherapeutics develops an investigational adenoviral immunotherapy platform for treating solid tumor cancers, with late-stage development of TILT-123 for head and neck cancer treatment. The company operates as a holding structure with distinct spin-out entities focused on clinical development and preclinical research.

BiotechHealthtechMedical Devices

Founders & leadership

Tiltbio was founded in 2013 by Akseli Hemminki.

AHAkseli Hemminki
Akseli HemminkiFounder and CEO

Investors · 3

Amadeus Capital PartnersreportedLondon · $50K – $12.7M

How we know: a partner's Signal profile · Not right? Tell us

Tesi (Finnish Industry Investment Ltd)reportedHelsinki · $5.4M – $16.2M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Funding

SEC filings, press & company announcements

$25M disclosed across 1 round · 2025

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 1

SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.

Companies working in the same space as Tiltbio.

Frequently asked questions

What does Tiltbio do?
TILT Biotherapeutics develops an investigational adenoviral immunotherapy platform for treating solid tumor cancers, with late-stage development of TILT-123 for head and neck cancer treatment. The company operates as a holding structure with distinct spin-out entities focused on clinical development and preclinical research.
Who founded Tiltbio?
Tiltbio was founded by Akseli Hemminki in 2013.
Who are Tiltbio's investors?
Tiltbio's investors include Lifeline Ventures, Amadeus Capital Partners, Tesi (Finnish Industry Investment Ltd).
How much funding has Tiltbio raised?
Tiltbio has disclosed $25M raised across 1 round.
Where is Tiltbio headquartered?
Tiltbio is headquartered in Helsinki, FI.